94
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! If you’re still wondering “What the heck happened with Moderna?” the latest episode of the video series STATus Report spells it out quite nicely. Also, a KFF poll shows 1 in 8 Americans have used a GLP-1 by now, Kura wins FDA approval for its AML drug, and more.
The need-to-know this morning
Table of Contents
Pharma can’t stop buying biotechs
The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy, for $9.2 billion, as the pharma giants widens its pipeline to counter the impending revenue hit as its mega-blockbuster Keytruda loses patent protection.
